Most Liquid Biotechnology Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1NAMS NewAmsterdam Pharma
222.43 M
(0.04)
 2.85 
(0.10)
2LSB LakeShore Biopharma Co,
201.56 M
 0.06 
 7.34 
 0.44 
3SYRE Spyre Therapeutics
198.34 M
 0.06 
 3.68 
 0.22 
4IMTXW immatics biotechnologies GmbH
178.39 M
 0.22 
 238.26 
 51.57 
5TRML Tourmaline Bio
147.76 M
 0.26 
 4.46 
 1.18 
6GRAL GRAIL, LLC
139.75 M
(0.01)
 5.13 
(0.07)
7DNTH Dianthus Therapeutics
138.94 M
 0.01 
 3.38 
 0.04 
8LENZ LENZ Therapeutics
138.69 M
 0.15 
 3.84 
 0.59 
9GPCR Structure Therapeutics American
136.28 M
 0.07 
 4.09 
 0.30 
10MGX Metagenomi, Common Stock
133.59 M
(0.20)
 5.22 
(1.05)
11BRNS Barinthus Biotherapeutics plc
133.15 M
(0.03)
 2.66 
(0.08)
12BCAX Bicara Therapeutics Common
129.03 M
 0.27 
 8.01 
 2.14 
13AVBP ArriVent BioPharma, Common
128.72 M
 0.18 
 3.53 
 0.65 
14KRRO Frequency Therapeutics
120.47 M
(0.04)
 5.07 
(0.18)
15NGNE Neurogene
109.68 M
 0.12 
 4.25 
 0.52 
16APGE Apogee Therapeutics, Common
108.08 M
 0.15 
 3.70 
 0.56 
17ZURA Zura Bio Limited
104.8 M
 0.09 
 4.31 
 0.39 
18LXEO Lexeo Therapeutics, Common
100.11 M
(0.16)
 5.21 
(0.83)
19KYTX Kyverna Therapeutics, Common
39.59 M
(0.13)
 5.04 
(0.65)
20TSBX Turnstone Biologics Corp
16.91 M
(0.22)
 8.51 
(1.87)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).